NCIC Clinical Trials Group

Members / Participants Membership Information Clinical Trials Meetings
&
Education
Publications

Lectures
Correlative Science / Tumour Bank Notices Fellowships Committees Papaya Mango EDC BARL

2012

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

21 Dec 2012

General

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group Central Office will be closed with limited staff over the holidays. Web-based applications (i.e. MANGO, GCP) will be available. Please see the Canadian Cancer Trials Group website ... http://www.ctg.queensu.ca ... for complete information.
Read more ....

Canadian Cancer Trials Group Tumour Bank - Holiday Closure
All centres participating on trials where fluids and tissues are collected and banked at the Canadian Cancer Trials Group Tumour Bank should not ship any specimens between December 13, 2012 and January 1, 2013 inclusive.
Read more ....

Cooperative Group Holiday Closures
We have collected and collated cooperative groups' holiday closures. A link to this information is available on the main Canadian Cancer Trials Group website at http://www.ctg.queensu.ca/2012HolidayClosureNotices/Cooperative_Group_holiday_hours _2012.pdf.
Read more ....

Happy Holidays and Happy New Year!!!!
On behalf of Canadian Cancer Trials Group's Central Office, we would like to wish everyone a very Merry Christmas, Happy Holidays, and Happy New Year. All the best for a restful and peaceful holiday season.
Read more ....

Bulletin in 2013
The first Bulletin of 2013 will be sent on Friday, January 4, 2013.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group LY.12 will officially close to further accrual to Randomization #2 (maintenance) as of 6:00 pm (EST) on Monday, December 31, 2012.
Read more ....

Trial Activation
Canadian Cancer Trials Group GA.2 (AG0212OG) -- INTEGRATE - A Randomized Phase II Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Esophago-Gastric Cancer (AEGC) -- was recently activated.
Read more ....

First Patient Enrolled onto Canadian Cancer Trials Group CX.5
We are extremely pleased to announce that the first patient has been enrolled onto Canadian Cancer Trials Group CX.5!!! Activated in August, 2012, CX.5 is one of two trials that was recently awarded funding from the Canadian Institutes of Health Research.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Dec 2012

EDC - Rave

Roster Office Reminders
To ensure centres do not experience delays when randomizing patients or accessing specific Canadian Cancer Trials Group resources over the holidays, we encourage centres to update trial Participant Lists and to request website, MANGO, and EDC access prior to December 14.
Read more ....

General

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group Central Office will be closed with limited staff over the holidays. Web-based applications (i.e. MANGO, GCP) will be available. Please see the Canadian Cancer Trials Group website ... www.ctg.queensu.ca ... for complete information.
Read more ....

Recent Publications
There were three recent publications -- one reporting results of Canadian Cancer Trials Group HD.7 (ECOG 2496), one reporting results of Canadian Cancer Trials Group MY.11, and a review article discussing the role of radiation therapy in early-stage Hodgkin lymphoma.
Read more ....

San Antonio Breast Cancer Symposium
Several Canadian Cancer Trials Group abstracts are being presented at the 35th Annual San Antonio Breast Cancer Symposium being held December 4-8, 2012 in San Antonio, Texas.
Read more ....

American Society of Hematology (ASH) Annual Meeting
Several Canadian Cancer Trials Group abstracts will be presented at the 54th ASH Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, Georgia.
Read more ....

Trial Management Group

Canadian Cancer Trials Group Tumour Bank - Holiday Closure
All centres participating on trials where fluids and tissues are collected and banked at the Canadian Cancer Trials Group Tumour Bank should not ship any specimens between December 13, 2012 and January 1, 2013 inclusive.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

23 Nov 2012

General

Recent Publications
There were two recent publications -- one related to Canadian Cancer Trials Group CO.17 published in Annals of Oncology, and the other reporting primary results of Canadian Cancer Trials Group SR.3 (EORTC 62931) published in The Lancet Oncology.
Read more ....

LACE-Bio-II Awarded NIH Grant
The Canadian Cancer Trials Group is very pleased to announce that Dr. Lesley Seymour and colleagues have been awarded a $2.3M R01 grant from the US NIH to identify, validate and implement prognostic / predictive biomarkers for adjuvant chemotherapy for early stage NSCLC.
Read more ....

Trial Management Group

Canadian Cancer Trials Group Tumour Bank - Holiday Closure
All centres participating on trials where fluids and tissues are collected and banked at the Canadian Cancer Trials Group Tumour Bank should not ship any specimens between December 13, 2012 and January 1, 2013 inclusive.
Read more ....

Trial Activation
Canadian Cancer Trials Group MDC.1 (SWOG S1117) - A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk MDS and CMML was recently activated.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

09 Nov 2012

Disease Site Updates

Canadian Cancer Trials Group MA.32 Accrual Update
As of November 8, 2012, there are over 3000 patients enrolled in Canadian Cancer Trials Group MA.32 -- A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. The target of 3582 patients is drawing near.
Read more ....

Canadian Cancer Trials Group Gynecology Site Committee Newsletter
The Fall issue of the Canadian Cancer Trials Group Gynecology Site Committee Newsletter is now available. The Newsletter provides updates on actively accruing Canadian Cancer Trials Group trials, and also includes a note from the Committee Chairs.
Read more ....

General

Recent Publications
There were three recent publications -- one reporting results of Canadian Cancer Trials Group MA.17L (a companion study to Canadian Cancer Trials Group MA.17), and two others reporting results of analyses conducted using data from other Canadian Cancer Trials Group-related trials.
Read more ....

Dr. Elizabeth Eisenhauer Awarded the Diamond Jubilee Medal
Dr. Elizabeth Eisenhauer has been awarded the Diamond Jubilee Medal in recognition of her "tremendous commitment to the advancement of cancer therapy, supportive care and prevention across Canada and internationally".
Read more ....

Office of Compliance and Oversight

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

26 Oct 2012

General

Recent Publications
There were two recent publications -- one describing a new certification program for biobanks developed by CTRNet, and the other reporting results of a substudy of Canadian Cancer Trials Group BR.21.
Read more ....

Navigating the Canadian Cancer Trials Group Bulletin
Are you having trouble seeing complete Bulletin items? If so, please don't forget to click on "View This Week's Bulletin" at top of the email and the Bulletin will open as a new page in your internet browser.
Read more ....

Office of Compliance and Oversight

Privacy and Confidentiality
The Office of Compliance and Oversight (OCO) is pleased to announce that the Canadian Cancer Trials Group Privacy and Confidentiality policy is now posted on the OCO website.
Read more ....

Trial Management Group

Trial Activations
Two trials were recently activated -- Canadian Cancer Trials Group CRC.7 (Alliance N1048), and Canadian Cancer Trials Group IND.211.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

12 Oct 2012

Disease Site Updates

Trial Status Updates for GI and Hematology
Memos updating the Canadian Cancer Trials Group's planned trial activity in the Gastrointestinal and Hematology sites are now posted to the respective external disease site websites, and notification has been sent to all disease site committee members.
Read more ....

General

Recent Publication
A publication related to Canadian Cancer Trials Group MA.17, recently published online in Annals of Oncology, has found that extended letrozole after 5 years of tamoxifen is better than placebo in disease-free survival in both pre- and postmenopausal women.
Read more ....

Unsubscribing to the Canadian Cancer Trials Group Bulletin -- REMINDER
Just a reminder that, although we hope that most people enjoy keeping up-to-date with all of the Canadian Cancer Trials Group-related news and activities and wish to continue to receive it, we now have a feature to "unsubscribe" from Canadian Cancer Trials Group Bulletin mailings.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group NEC.2 (CALGB 80701) was closed to accrual on October 1, 2012 after achieving its target accrual of 138 patients.
Read more ....

Withdrawal of Consent Policy
Canadian Cancer Trials Group has developed a new Withdrawal of Consent Policy that we are now pleased to roll out to centres.
Read more ....

Trial Activation
Canadian Cancer Trials Group MEC.3 (ECOG 1609) - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma - was centrally activated on October 2, 2012.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

28 Sep 2012

General

Canadian Cancer Trials Group Office Closure
The Canadian Cancer Trials Group will be closed Monday, October 8, 2012 for Thanksgiving.
Read more ....

OV.21 and Ovarian Cancer Canada
The Canadian Cancer Trials Group and Ovarian Cancer Canada have teamed up to promote awareness of OV.21, a phase II/III trial comparing intraperitoneal vs intravenous delivery of standard chemotherapy drugs to treat ovarian cancer.
Read more ....

Canadian Cancer Trials Group 2013 Spring Meeting -- SAVE THE DATE
SAVE THE DATE -- The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26-28, 2013 at the Delta Chelsea Hotel in Toronto.
Read more ....

Office of Compliance and Oversight

Trial Status Update Form
The Office of Compliance and Oversight (OCO) has replaced the "Notification of Unreported SAE/SU/IB/PM to Local REB" form with a new "Trial Status Update" (TSU) form.
Read more ....

Trial Management Group

First US Patient Enrolled to OV.21
The Canadian Cancer Trials Group OV.21 team is pleased to announce that international collaboration with the United States through SWOG has led to patient accrual to the OV.21 trial.
Read more ....

Trials Closed to Accrual
Canadian Cancer Trials Group IND. 204 - A Phase II Study of PX-866 in Patients with Glioblastoma Multiforme at Time of First Relapse or Progression -- was closed to accrual on September 24, 2012, after achieving its protocol-mandated accrual target.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

14 Sep 2012

General

Recent Publications
There were two recent publications -- one reporting the final results of Canadian Cancer Trials Group IND.189, and the other reporting final results of Canadian Cancer Trials Group PR.7 published in the New England Journal of Medicine.
Read more ....

Chair and Chair-Elect of the IND Committee
The Canadian Cancer Trials Group is very pleased to announce that Dr. Kim Chi will remain as Chair of the Investigational New Drug Committee for a further year, and Dr. Scott Laurie has been named the IND Committee's Incoming Chair.
Read more ....

Office of Compliance and Oversight

New Harmonized Generic Informed Consent Form Template
The Canadian Cancer Trials Group is very pleased to announce that, in conjunction with provincial ethics boards, the BCCA Research Ethics Board and the Ontario Cancer Research Ethics Board, it has developed a new harmonized generic informed consent template.
Read more ....

Trials Added to Web-Based Ethics Utility
Canadian Cancer Trials Group AL.3, REC.1, BR.22, CX.4, SR.4, LY.7, LY.9 and OV.16 have been added to the Compliance Group's web-based ethics utility in order to assist Canadian centres with ongoing compliance.
Read more ....

Trial Management Group

Canadian Cancer Trials Group MA.32 Trial Accrual
We are very pleased to announce that collaborations with the UK ICR-CTSU and IBCSG have resulted in two recent patient accruals -- one from the UK and one from Switzerland.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

04 Sep 2012

General

Unsubscribing to the Canadian Cancer Trials Group Bulletin
Although we hope that most people enjoy keeping up to date with all of the Canadian Cancer Trials Group-related news and activities and wish to continue to receive it, we now have a feature to "unsubscribe" from Canadian Cancer Trials Group Bulletin mailings.
Read more ....

The Canadian Cancer Trials Group Bulletin -- Our Apologies
Canadian Cancer Trials Group sincerely apologizes for the incident resulting in the "Reply All" messages being sent to the Canadian Cancer Trials Group Bulletin recipients. Our IT department has investigated and has put systems in place to avoid future occurrences.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 Aug 2012

General

Recent Publications
There were two recent publications -- one reporting the final results of Canadian Cancer Trials Group MAC.7 (SWOG0226) published in NEJM, and the other related to Canadian Cancer Trials Group HD.6 discussing the role of radiation therapy in the treatment of early stage Hodgkin lymphoma.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group CL.3 (CALGB 10404) has met its accrual goal and will close to further accrual at 5:00 pm today, Friday, August 17.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

03 Aug 2012

General

Canadian Cancer Trials Group CO.17 Continues to Impact Practice Standards
The US FDA has approved a genetic test to help physicians determine which patients with metastatic colorectal cancer are likely to benefit from the drug cetuximab (Erbitux). Approval of the test was based on samples collected as part of Canadian Cancer Trials Group CO.17.
Read more ....

Canadian Cancer Trials Group Holiday Closure
Monday, August 6, 2012 is a Civic Holiday (in Canada), and the Canadian Cancer Trials Group will be closed. Regular business hours will resume on Tuesday, August 7 at 8:00 am EDT.
Read more ....

Trial Management Group

Trial Activations
Three trials were recently activated -- Canadian Cancer Trials Group IND.194, Canadian Cancer Trials Group IND.213, and Canadian Cancer Trials Group.CX.5 (GCIG: SHAPE).
Read more ....

Trial Closed to Accrual
One trial -- Canadian Cancer Trials Group IND.191 -- was closed to accrual on July 26, 2012.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

20 Jul 2012

General

Canadian Cancer Trials Group Holiday Closure
Monday, August 6, 2012 is a Civic Holiday (in Canada), and the Canadian Cancer Trials Group will be closed. Regular business hours will resume on Tuesday, August 7 at 8:00 am EDT.
Read more ....

Office of Compliance and Oversight

Changes to the Ethics Research Associate Centre Assignments
Please note that the Canadian Cancer Trials Group Ethics Research Associate contact has changed for some centres.
Read more ....

Trial Management Group

Canadian Cancer Trials Group SC.23 Accrues 100th Patient
Canadian Cancer Trials Group is very pleased to announce that SC.23 had its 100th patient randomized on July 19, 2012!
Read more ....

Trial Activations
Two trials were recently activated -- Canadian Cancer Trials Group PA.6 (PRODIGE/ACCORD24) was centrally activated on July 18, 2012 and Canadian Cancer Trials Group SR.6 (SARC021) was activated today, July 20, 2012.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Jul 2012

General

Recent Publication
Results of a study utilizing material from Canadian Cancer Trials Group MA.12 to evaluate the prognostic and predictive significance of intrinsic subtypes identified by both the PAM50 gene set and by immunohistochemistry was recently published in Clinical Cancer Research.
Read more ....

Dr. Tony Fields Named to the Order of Canada
The Canadian Cancer Trials Group is extremely pleased to announce that Dr. Tony Fields, long-time member of the Group, has been named to the Order of Canada which recognizes a lifetime of outstanding achievement, dedication to the community and service to the nation.
Read more ....

Office of Compliance and Oversight

Ethics Research Associate Centre Assignments
The Canadian Cancer Trials Group Central Office Ethics Research Associate has changed for some centres.
Read more ....

Trial Management Group

OV.21 Accrual Surpasses 100 Patients
Canadian Cancer Trials Group is very pleased to announce that on July 3, 2012, OV.21 hit the 100 patient mark. The trial is well on its way to reaching its target accrual of 150 patients for the phase II portion of this important trial.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Jun 2012

General

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, July 2, 2012 in observance of Canada Day. Regular business hours will resume on Tuesday, July 3 at 8:00 am EDT.
Read more ....

Office of Compliance and Oversight

MA.21 Added to Web-Based Ethics Utility
Canadian Cancer Trials Group MA.21 has been added to the Compliance Group's web-based ethics utility in order to assist Canadian centres with ongoing compliance.
Read more ....

EDC SAEs and Concomitant Medications
As part of the process for submitting an initial SAE, CRAs should update the running log of concomitant medications with all medications the patient was receiving up until the time of SAE reporting and including those used to treat the SAE.
Read more ....

Trial Management Group

Trial Activations
Three investigational new drug trials were recently activated -- Canadian Cancer Trials Group IND.193, IND.209, and IND.210.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

08 Jun 2012

Finance and Operations

2012 Spring Meeting Expense Claims
If you received a full-funded invitation to the 2012 Spring Meeting of Participants, please read the following carefully ...
Read more ....

General

Dr. Elizabeth Eisenhauer, Dr. Lesley Seymour and the Canadian Cancer Trials Group's Investigational New Drug Program
As of July 1, 2012, Dr. Elizabeth Eisenhauer will be stepping down from her position as Director of the IND Program. Dr. Lesley Seymour will assume the role of Director of our IND Program.
Read more ....

Dr. Ming-Sound Tsao
Dr. Ming-Sound Tsao was recently honoured with the Canadian Cancer Society's prestigious O. Harold Warwick Prize, which is given to a scientist whose research has had a major impact on cancer control in Canada.
Read more ....

Canadian Cancer Trials Group News From ASCO 2012
A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation were presented at the ASCO 2012 Annual Meeting, including the results of two breast cancer studies that were highlighted in the media and by ASCO.
Read more ....

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards.
Read more ....

Recent Publication
There was one recent publication.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

25 May 2012

General

ASCO 2012
A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation are being presented at the American Society of Clinical Oncology Annual Meeting in Chicago, June 1-5, 2012.
Read more ....

Recent Publication
A recent publication reports the results of a pooled analysis of Canadian Cancer Trials Group BR.10 and CALGB B-9633 which explored the prognostic and predictive effects of the new T-size descriptors and KRAS mutation status in patients with node-negative NSCLC.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group SC.20, and its companion study SC.20U, was closed to accrual today, May 25, after reaching its accrual target of 850 patients.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

11 May 2012

General

Trial Activation
One trial -- IND.208: A Phase I/II Study of the PI3 Kinase Inhibitor BKM120 Given in Combination with Panitumumab in Patients with Metastatic or Advanced Ras Wild-type Colorectal Cancer -- was recently activated.
Read more ....

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, May 21, 2012 to celebrate Victoria Day. Regular business hours will resume on Tuesday, May 22 at 8:00 am EDT.
Read more ....

Recent Publications
There were two recent publications, including one reporting the primary results of Canadian Cancer Trials Group OV.14 (NSGO OC9804).
Read more ....

Canadian Cancer Trials Group Spring Meeting: Claiming CME Credits
The 2012 Annual Spring Meeting of Participants is an Accredited Group Learning Activity (Section 1) of the Royal College of Physicians and Surgeons of Canada. Meeting participants may be eligible to receive CME credits.
Read more ....

Spring Meeting 2012 Expense Claim Forms
When sending in your Spring Meeting 2012 Expense Claim Form, please be sure to read the Travel Policy carefully to help ensure your claims are processed as quickly and efficiently as possible. Incomplete or inadequate claims will be returned.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

26 Apr 2012

General

2012 Spring Meeting Event -- Cosbie Lecture
We are very pleased to announce Dr. Robert Califf as the 2012 "Cosbie Lecturer". The title of Dr. Califf's talk is "The American Clinical Trials Enterprise: Are We Reaching the Tipping Point for Transformation?"
Read more ....

2012 Spring Meeting Trial Reports
The 2012 Spring Meeting Trial Reports are now available on the Canadian Cancer Trials Group members-only website using this link ... http://www.ctg.queensu.ca/trials/.
Read more ....

Recent Publication
The primary report for Canadian Cancer Trials Group CRC.2 (NCCTG N0147) was recently published in the Journal of the American Medical Association.
Read more ....

Office of Compliance and Oversight

Office of Compliance and Oversight (OCO) - New Website
OCO is pleased to announce the release of its updated website. All content related to Audit, Monitoring, Ethics, Safety, and the Centre Performance Index (CPI), as well as associated Forms and Resources and News is available through the new website.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Apr 2012

General

2012 Spring Meeting of Participants -- Wireless Internet
For 2012, we have arranged for free wireless internet to be available in the meeting rooms and in Churchill Court of the Delta Chelsea Hotel. Access will be available to all participants for the duration of Spring Meeting beginning Friday, 27 April 2012.
Read more ....

2012 Spring Meeting Trial Reports
The 2012 Spring Meeting Trial Reports will be available by Tuesday, April 17 on the Canadian Cancer Trials Group members-only website using this link ... http://www.ctg.queensu.ca/trials/.
Read more ....

2012 Spring Meeting of Participants -- Registration
On-line registration for the 2012 Spring Meeting of Participants will be closed at 4:00 pm on Friday, 20 April 2012. If you have not already registered, you should do so as soon as possible.
Read more ....

2012 Spring Meeting Event -- Cosbie Lecture
We are very pleased to announce Dr. Robert Califf as the 2012 "Cosbie Lecturer". The title of Dr. Califf's talk is "The American Clinical Trials Enterprise: Are We Reaching the Tipping Point for Transformation?"
Read more ....

Next Bulletin
The next edition of the Bulletin will be sent on Thursday, April 26, 2012.
Read more ....

Trial Management Group

Trial Activation
There was one recent trial activation. Canadian Cancer Trials Group MA.34 (BIG 4‐11) -- The APHINITY TRIAL -- was centrally activated April 5, 2012.
Read more ....

Trials Closed to Accrual
Three trials have been closed to accrual -- Canadian Cancer Trials Group PRC.2 (CALGB90202), Canadian Cancer Trials Group IND.200, and Canadian Cancer Trials Group IND.203.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

30 Mar 2012

General

Holiday Closure
The Canadian Cancer Trials Group will be closed on Friday, April 6, 2012 in observance of Good Friday. Regular business hours will resume on Monday, April 9 at 8:00 am EDT.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group ES.2 (TROG 03.01) -- A Randomized Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated with Radiotherapy Versus Chemo-Radiotherapy -- was closed to accrual on March 21, 2012.
Read more ....

Implementing Canadian Cancer Trials Group Protocol-Specific Training
Canadian Cancer Trials Group, as sponsor in Canada, is required to ensure personnel at our member sites have undergone ICH-GCP and ethical trial conduct training prior to participating on our trials.
Read more ....

Canadian Cancer Trials Group's Lost to Follow-Up Policy
Canadian Cancer Trials Group has developed a new Lost to Follow-Up Policy that we are now pleased to roll out to centres.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

16 Mar 2012

Finance and Operations

2012 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2012 Annual Spring Meeting of Participants will be held April 27 - 29, 2012 at the Delta Chelsea Hotel in Toronto.
Read more ....

General

Two Canadian Cancer Trials Group Investigators Recognized by NCI
Dr. Susan Ellard and Dr. Muhammad Salim were recently recognized by the NCI and CTSU for being two of the top-enrolling individual investigators to Cooperative Group treatment trials via the CTSU in 2010.
Read more ....

Trial Closed to Accrual
Canadian Cancer Trials Group IND.187 -- A Phase I Study of AZD2281 in Combination with Irinotecan in Patients with Locally Advanced or Metastatic Incurable Colorectal Cancer -- was closed to accrual on March 8, 2012 after establishing the recommended phase II dose.
Read more ....

Recent Publications
There were four recent publications -- one reporting the primary results of Canadian Cancer Trials Group BL.7 (EORTC 30987), another related to Canadian Cancer Trials Group MA.5, a statistics publication, and another general publication.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

02 Mar 2012

General

Recent Publications
There were 4 recent publications ... one reporting results of Canadian Cancer Trials Group BL.7 (EORTC 30987), one related to Canadian Cancer Trials Group BR.18, one reporting final results of Canadian Cancer Trials Group IND.162, and another related to OV.17 (GINECO CALYPSO).
Read more ....

Dr. Elizabeth Eisenhauer Named NDDO Honorary Award Lecturer
Congratulations to Dr. Elizabeth Eisenhauer for being named the 2012 recipient of the NDDO Honorary Award Lecture for her contributions to cancer drug development.
Read more ....

Trial Management Group

Transition of Leadership of the Canadian Cancer Trials Group CRA Executive
After 7 years of outstanding leadership, Brenda Kowaleski will be stepping down as Chair of the Clinical Research Associates Executive Committee. Succeeding Brenda in this important role will be Lynn Dwernychuk from the Saskatoon Cancer Centre.
Read more ....

Trial Closed to Accrual
Canadian Cancer Trials Group IND.202 - Randomized Phase II Study of Interleukin-21 (rIL-21) versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma - was closed to accrual on February 29, 2012.
Read more ....

CRA Volunteers Needed!
The Clinical Research Associates Executive Committee is actively seeking a CRA representative for a number of the following Canadian Cancer Trials Group Disease Site Committee Executives.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 Feb 2012

General

Canadian Cancer Trials Group Central Office and BARL Holiday Closure
The Canadian Cancer Trials Group (Central Office) will be closed on Monday, February 20, 2012 to celebrate Family Day. Bay Area Research Logistics (BARL) will be also closed on Monday for Family Day.
Read more ....

Recent Publications
There were 4 recent publications -- one reporting results of a substudy examining bone strength in a subset of women who participated on Canadian Cancer Trials Group MAP.3; one reporting the health-related quality of life results from Canadian Cancer Trials Group OV.17; and two meta-analyses that included data from Canadian Cancer Trials Group MA.4, MA.5, and MA.21.
Read more ....

2012 Spring Meeting of Participants
The Canadian Cancer Trials Group 2012 Annual Spring Meeting of Participants will be held April 27-29, 2012 at the Delta Chelsea Hotel in Toronto. Full-Funded invitations were sent electronically January 25, 2012, and Non-Funded invitations were sent today, February 17.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

03 Feb 2012

General

Canadian Cancer Trials Group Receives CIHR Funding
We are extremely pleased to announce that the Canadian Cancer Trials Group has received CIHR funding totalling almost $4M to support two Canadian Cancer Trials Group international trials -- CX.5 and GA.1.
Read more ....

Recent Publications
There were four recent publications -- two related to Canadian Cancer Trials Group CO.14 and CO. 15, another related to Canadian Cancer Trials Group BR.21, and the final results of HD.6 are now in print in NEJM.
Read more ....

2011 ASCO Annual Report on Progress Against Cancer
Two Canadian Cancer Trials Group-led trials (MAP.3 and MA.20) and one trial that included Canadian Cancer Trials Group participation (OV.19) were included as "Major Advances" in ASCO's 2011 Annual Report on Progress Against Cancer.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

23 Jan 2012

Finance and Operations

20 January 2012 Bulletin
Due to computer issues, we were unable to send the Bulletin scheduled for Friday, January 20, 2012. As a result, we are sending the Bulletin today ... Monday, January 23. The next Bulletin will be sent as originally planned on Friday, February 3, 2012.
Read more ....

Trial Management Group

Working Group on Economic Analysis Has A New Name
The Working Group on Economic Analysis (WGEA) has a new name! The former WGEA is now the Committee on Economic Analysis (CEA).
Read more ....

CRA Volunteers Needed!
The Clinical Research Associates Executive Committee (CRAEC) is actively seeking a CRA representative for each of the following Canadian Cancer Trials Group Disease Site Committee Executives -- Melanoma, Symptom Control, Gastrointestinal.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Jan 2012

General

The Canadian Cancer Trials Group Welcomes New Chairs to Gynecology Committee
We are very pleased to announce that Drs Hal Hirte and Michael Fung Kee Fung are the new Co-Chairs of the Canadian Cancer Trials Group's Gynecology Site Committee. We wish to express our deep gratitude to Drs Gavin Stuart and Amit Oza for their outstanding leadership.
Read more ....

CCS Listing of Top 10 Breakthroughs of 2011
The results of THREE Canadian Cancer Trials Group-led clinical trials were included in the Canadian Cancer Society's listing of the top 10 breakthroughs of 2011.
Read more ....

Recent Publications
There were 4 recent publications -- one related to Canadian Cancer Trials Group MA.5, one related Canadian Cancer Trials Group PA.3, and two other general publications.
Read more ....

Permanent Trial Closures
Following our annual Permanent Trial Closure Assessment, the Canadian Cancer Trials Group has identified those phase I-III Canadian Cancer Trials Group-led trials that will be permanently closed.
Read more ....

Canadian Cancer Trials Group OV.19 (MRC ICON7) in the NEJM
Results of Canadian Cancer Trials Group OV.19 (MRC ICON7) were published in the 29 December 2011 issue of the New England Journal of Medicine.
Read more ....

Trial Management Group

The Canadian Cancer Trials Group Welcomes New Members to the CRA Executive Committee
The Canadian Cancer Trials Group would like to welcome six new members to the newly-formed Canadian Cancer Trials Group Clinical Research Associates Executive Committee.
Read more ....

If you have any questions, comments or suggestions, please contact Heather Stanton


Canadian Cancer Trials Group Bulletins